{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:09:22Z","timestamp":1789495762067,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Autologous stem cell transplantation (ASCT) is integral to treating newly diagnosed multiple myeloma (MM). While novel therapies improve response rates, they also hinder stem cell mobilization. This study evaluates the impacts of induction regimens on mobilization, collection, and ASCT outcomes. We analyzed 228 patients divided into three groups: bortezomib-thalidomide-dexamethasone (VTD, <jats:italic>N<\/jats:italic>\u2009=\u2009117); bortezomib-lenalidomide-dexamethasone (VRD, <jats:italic>N<\/jats:italic>\u2009=\u200957); and daratumumab-VTD (DVTD, <jats:italic>N<\/jats:italic>\u2009=\u200954). Baseline characteristics showed no significant differences among the groups. Chemo-mobilization was most common in VTD (20.5%) compared to VRD (12.3%) and DVTD (5.6%). Total CD34 + cell yield (x10\u2076\/kg) was highest in VTD (7.1\u2009\u00b1\u20093.5) compared to VRD (5.8\u2009\u00b1\u20093.2) and DVTD (5.4\u2009\u00b1\u20092.4) [<jats:italic>p<\/jats:italic>\u2009=\u20090.0001]. Second mobilization was required most frequently in VRD (40.4%) compared to DVTD (24.1%) and VTD (16.2%) [<jats:italic>p<\/jats:italic>\u2009=\u20090.0010]. Plerixafor use was highest in VRD (40.4%) compared to DVTD (24.1%) and VTD (12.0%) [<jats:italic>p<\/jats:italic>\u2009=\u20090.0001]. Mobilization duration was longest in VRD (4.0\u2009\u00b1\u20091.9 days) and shortest in VTD (3.2\u2009\u00b1\u20091.7 days) [<jats:italic>p<\/jats:italic>\u2009=\u20090.0038]. Infused CD34 cells and platelet engraftment times were comparable among groups. Neutrophil engraftment was delayed in VRD (12.1\u2009\u00b1\u20090.9 days) compared to DVTD (11.8\u2009\u00b1\u20091.2) and VTD (11.6\u2009\u00b1\u20090.7) [<jats:italic>p<\/jats:italic>\u2009=\u20090.0014]. Prompt stem cell collection is essential in lenalidomide regimens to minimize mobilization challenges. While DVTD demonstrated comparable mobilization efficiency, it produced fewer CD34 cells than VTD, indicating potential challenges.<\/jats:p>","DOI":"10.1007\/s00277-025-06372-4","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:54:06Z","timestamp":1745556846000},"page":"2297-2304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Soyean","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"6372_CR1","doi-asserted-by":"publisher","unstructured":"Padala SA et al (2021) Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel) 9(1). https:\/\/doi.org\/10.3390\/medsci9010003","DOI":"10.3390\/medsci9010003"},{"issue":"10068","key":"6372_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM et al (2017) Bortezomib with Lenalidomide and dexamethasone versus Lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527. https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X","journal-title":"Lancet"},{"issue":"12","key":"6372_CR3","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","volume":"7","author":"M Roussel","year":"2020","unstructured":"Roussel M et al (2020) Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol 7(12):e874\u2013e883. https:\/\/doi.org\/10.1016\/S2352-3026(20)30356-2","journal-title":"Lancet Haematol"},{"issue":"2","key":"6372_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"key":"6372_CR5","doi-asserted-by":"publisher","unstructured":"Tricot G et al (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85. 2588\u2013596. https:\/\/doi.org\/10.1182\/blood.V85.2.588.588","DOI":"10.1182\/blood.V85.2.588.588"},{"issue":"10","key":"6372_CR6","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","volume":"13","author":"W Bensinger","year":"1995","unstructured":"Bensinger W et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13(10):2547\u20132555. https:\/\/doi.org\/10.1200\/JCO.1995.13.10.2547","journal-title":"J Clin Oncol"},{"issue":"1","key":"6372_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood.V86.1.390.bloodjournal861390","volume":"86","author":"G Schiller","year":"1995","unstructured":"Schiller G et al (1995) Transplantation of CD34\u2009+\u2009peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86(1):390\u2013397. https:\/\/doi.org\/10.1182\/blood.V86.1.390.bloodjournal861390","journal-title":"Blood"},{"issue":"12","key":"6372_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/sj.bmt.1702066","volume":"24","author":"JA Perez-Simon","year":"1999","unstructured":"Perez-Simon JA et al (1999) Clinical significance of CD34\u2009+\u2009cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transpl 24(12):1279\u20131283. https:\/\/doi.org\/10.1038\/sj.bmt.1702066","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"6372_CR9","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1182\/blood-2010-12-322214","volume":"117","author":"M Korbling","year":"2011","unstructured":"Korbling M, Freireich EJ (2011) Twenty-five years of peripheral blood stem cell transplantation. Blood 117(24):6411\u20136416. https:\/\/doi.org\/10.1182\/blood-2010-12-322214","journal-title":"Blood"},{"issue":"5","key":"6372_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jca.20246","volume":"25","author":"ZN Ozkurt","year":"2010","unstructured":"Ozkurt ZN et al (2010) Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 25(5):280\u2013286. https:\/\/doi.org\/10.1002\/jca.20246","journal-title":"J Clin Apher"},{"issue":"10","key":"6372_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/leu.2011.131","volume":"25","author":"F Cavallo","year":"2011","unstructured":"Cavallo F et al (2011) Stem cell mobilization in patients with newly diagnosed multiple myeloma after Lenalidomide induction therapy. Leukemia 25(10):1627\u20131631. https:\/\/doi.org\/10.1038\/leu.2011.131","journal-title":"Leukemia"},{"issue":"4","key":"6372_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","volume":"16","author":"P Wuchter","year":"2010","unstructured":"Wuchter P et al (2010) Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transpl 16(4):490\u2013499. https:\/\/doi.org\/10.1016\/j.bbmt.2009.11.012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"6372_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK et al (2023) Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(12):1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"6372_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41409-024-02260-z","volume":"59","author":"F Fazio","year":"2024","unstructured":"Fazio F et al (2024) Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the multiple myeloma group. Bone Marrow Transpl 59(6):896\u2013898. https:\/\/doi.org\/10.1038\/s41409-024-02260-z","journal-title":"Bone Marrow Transpl"},{"issue":"Supplement 1","key":"6372_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134538","volume":"136","author":"A Perrot","year":"2020","unstructured":"Perrot A et al (2020) Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial. Blood 136(Supplement 1):39. https:\/\/doi.org\/10.1182\/blood-2020-134538","journal-title":"Blood"},{"issue":"9","key":"6372_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114(9):1729\u20131735. https:\/\/doi.org\/10.1182\/blood-2009-04-205013","journal-title":"Blood"},{"issue":"9","key":"6372_CR17","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S et al (2007) Impact of Lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21(9):2035\u20132042. https:\/\/doi.org\/10.1038\/sj.leu.2404801","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06372-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06372-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06372-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:59Z","timestamp":1746414839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06372-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6372"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06372-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (IRB number: H-2207-083-1339) before the initiation of the study. This study was conducted in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. As a retrospective study, the requirement for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}